Bryon Cipriani
Position: Chief Executive Officer
Company: Aranscia
Professional Summary
Bryon Cipriani currently serves as the Chief Executive Officer of Aranscia, a company specializing in human-first diagnostic solutions. With nearly 30 years of experience in the healthcare industry, Bryon's career spans various roles across clinical, revenue cycle, and technology companies. His expertise includes designing medication management solutions, implementing accountable care programs, and consulting for molecular diagnostic laboratories. Bryon’s background has positioned him ideally to lead Aranscia's strategic direction and innovation within the field of precision medicine.
Leadership and Contributions
- Architect of Synergistic Team and Platform: Bryon leads the architecture of Aranscia's synergistic team and platform, leveraging his in-depth industry knowledge.
- Strategic Acquisitions: Recently, under his leadership, Aranscia announced the acquisition of YouScript from Invitae, expanding their portfolio in precision medicine workflow solutions (June 2023).
- Innovative Collaborations: He announced a collaboration with Signature RX to optimize GLP-1 medication management, underscoring Aranscia's commitment to leveraging evidence-based insights (June 2024).
Company Overview: Aranscia
Aranscia focuses on unlocking the power of precision medicine by serving clinical professionals within the care workflow. The company delivers high-utility, workflow-friendly solutions across multiple clinical settings, supporting thousands of clients.
Key Services and Innovations
- Diagnostic Software and Services: Aranscia offers a suite of diagnostic software and services aimed at improving care outcomes through timely and accurate data delivery.
- Precision Medicine Programs: The company has established turnkey programs in pharmacogenomics, infectious disease management, precision oncology, and genetic screening.
- Lab-Agnostic Services: Facilitates and supports all testing needs independently of specific laboratory affiliations.
Notable Leadership Team
- Dave Copas (Board of Directors): Experienced with over 35 years in healthcare IT and operations, previously co-founded the MedTek21 platform.
- Joe Spinelli (Chief Strategy Officer): Spearheads product and corporate development, with a strong background in investment and technology.
- Grattan Smith (Chief Revenue Officer): Oversees sales operations, bringing diverse experience from Fortune 500, growth-stage companies, and startups.
- H. Rey Stroube IV (CFO): Senior finance leader with over 30 years of experience, previously CFO at Baylor Genetics Laboratories.
- Dr. Joel Diamond (Chief Medical Officer): Renowned for practical clinical and technology implementation, adjunct professor at the University of Pittsburgh.
- Houda Hachad (VP of Clinical Operations): Active in CPIC and PharmVar, focused on pharmacogenomics standardization.
- Kristine Ashcraft (President, YouScript): A leading figure in pharmacogenomics with over 25 years of experience.
Recent News and Announcements
- March 2024: Bryon Cipriani discussed the acquisition of YouScript at #ViVE2024, emphasizing growth and diversification in precision medicine.
- June 2024: Announced a personalized medication management program for GLP-1 treatments in collaboration with Signature RX.
- December 2023: Dr. Joel Diamond, Aranscia’s CMO, interviewed on HIMSS TV regarding the mainstream adoption of pharmacogenetics.
Contact Information
Email: info@aranscia.com
Phone: 888-958-2298
Address: 4035 Willowbend Blvd., Suite #400, Houston, Texas 77025
Conclusion
Bryon Cipriani’s leadership at Aranscia has driven significant advancements in precision medicine and diagnostics, ensuring that clinical professionals receive the most accurate and actionable data for patient care. Under his direction, Aranscia is poised to remain a leader in diagnostic innovations, offering scalable and efficient solutions tailored for long-term healthcare improvements.
